Fanghanel-S G, Larraza O, Arauco R, Esquivel R, Martinez Campos A, Valverde-R C
Clin Endocrinol (Oxf). 1978 Oct;9(4):289-96. doi: 10.1111/j.1365-2265.1978.tb02213.x.
The therapeutic effectiveness of bromocriptine as well as the post-operative ultrastructural aspects of treated pituitary adenomas were investigated in five acromegalic patients. Although concentrations of GH basal decreased and the glucose tolerance test and the TSH responses were significantly improved, the release of GH induced by TRH was not prevented by the dopaminergic agonist. Adenomatous cells were densely granulated and contained a dilated endoplasmic reticulum. Misplaced exocytosis was frequently observed. These findings clearly indicate that bromocriptine inhibits the spontaneous release of GH but does not interfere with the abnormal GH response to TRH. This suggests a separate site of action. The drug seems not to block the synthesizing activity of the adenomatous cell, a finding in accordance with clinical observations that warns against its use as a single therapeutic agent.
对5例肢端肥大症患者研究了溴隐亭的治疗效果以及经治疗的垂体腺瘤术后超微结构方面的情况。虽然基础生长激素（GH）浓度下降，葡萄糖耐量试验及促甲状腺激素（TSH）反应显著改善，但多巴胺能激动剂并不能阻止促甲状腺激素释放激素（TRH）诱导的GH释放。腺瘤细胞颗粒密集，内质网扩张，常可见错位的胞吐作用。这些发现清楚地表明，溴隐亭抑制GH的自发性释放，但不干扰GH对TRH的异常反应。这提示了一个单独的作用位点。该药似乎并不阻断腺瘤细胞的合成活性，这一发现与临床观察结果一致，警示不要将其用作单一治疗药物。
